Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0095 EUR | -.--% | +46.15% | -5.00% |
2021 | Ovoca Bio : Enrolls First Patient in Phase 2 Trial for Hypoactive Sexual Desire Disorder Treatment | MT |
Business Summary
At the end of 2022, the Group had a product in phase III clinical development (Orenetide).
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 88,458,806 | 42,053,448 ( 47.54 %) | 6,895,000 ( 7.795 %) | 47.54 % |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Silver Star Ltd. (Bermuda)
|
Miscellaneous
|
Sector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
-5.00% | 840K | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- OVXA Stock
- Company Ovoca Bio plc